Brain-derived neurotrophic factor, sex hormones and cognitive decline in male patients with schizophrenia receiving continuous antipsychotic therapy

Table 2 Comparison of cognitive scores between chronic antipsychotic-treated male schizophrenia patients and healthy controls

Cognitive index	CATM patients	Controls	F (P value)	MD (95%CI)
DCT	304.1 ± 215.0	130.8 ± 43.3	50.8 (< 0.001)	173.2 (124.0 to 222.4)
SVF	16.0 ± 7.8	27.6 ± 7.9	0.0 (< 0.001)	-11.6 (-8.7 to -14.5)
SS	11.6 ± 4.2	16.4 ± 4.2	0.1 (< 0.001)	-4.7 (-3.4 to -6.1)
TMT-A	101.3 ± 57.9	50.0 ± 21.7	26.5 (< 0.001)	51.3 (35.6 to 67.0)
BDT	17.1 ± 9.0	31.8 ± 8.8	0.2 (< 0.001)	-14.7 (-11.6 to -17.8)
PASAT correct	19.8 ± 10.5	34.0 ± 10.2	0.0 (< 0.001)	-14.1 (-9.5 to -18.7)
PASAT try	23.9 ± 11.0	36.9 ± 10.7	0.4 (<0.001)	13.0 (-8.2 to 17.8)

95%CI: 95% confidence interval; DCT: Digit Cancellation Test; SVF: Semantic Verbal Fluency; SS: Spatial Span Test; PASAT: Paced Auditory Serial Addition Test; TMT-A: Trail Making Task; BDT: Block Design Test.